BioPharma Dive - Latest News

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.

Feb 14, 2025 - 17:53
 0
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.

Read More

Tags:

Previous Article

It's A $15,000 Honda S2000 With One Photo And Obvious Mods, What's The Worst Tha...

Next Article

Trump administration to fire thousands at health agencies

Related Posts

Biogen inks royalty deal to gain funding for lupus drug R&D

Biogen inks royalty deal to gain funding for lupus drug...

Feb 12, 2025  0

FTC retains stricter merger guidelines under Trump

FTC retains stricter merger guidelines under Trump

Feb 19, 2025  0

Vertex ends gene editing research pact with Verve

Vertex ends gene editing research pact with Verve

Feb 27, 2025  0